Description
Dutahair (Dutasteride) – The agent for the treatment of benign prostatic hyperplasia. Inhibits 5α-reductase isozymes 1 and 2, which are responsible for the conversion of testosterone to 5α-dihydrotestosterone. DHT androgen is the main responsible for the hyperplasia of the glandular prostate tissue.
The maximum impact of dutasteride to reduce DHT concentration is dose dependent and is observed within 1-2 weeks. after the start of treatment. After 1 and 2 weeks. dutasteride receiving a dose of 0.5 mg / day average value dihydrotestosterone concentration in serum is reduced by 85% and 90%.
Dutasteride reduces the size of the prostate, improves urination, and reduces the risk of acute urinary retention and the need for surgical treatment. Treatment of benign prostatic hyperplasia.
Dosing regimen of Dutahair
Adult males, including elderly patients, the recommended dose ingestion of 500 mg 1 time / day. Treatment should be continued for at least 6 months.
On the part of the reproductive system: erectile dysfunction, the change (decrease) libido, ejaculation disorder, gynecomastia (including pain and breast enlargement).
Allergic reactions: in some cases – a rash, pruritus, urticaria, localized swelling
Special instructions of Dutahair
Caution should be used in patients with impaired liver function, as dutasteride undergoes extensive metabolism in the liver, and its T 1/2 is 3-5 weeks.
Patients with benign prostatic hyperplasia is necessary to carry out a digital rectal examination and other methods of investigation of the prostate prior to treatment with dutasteride and periodically repeating these studies in the treatment process in order to avoid the development of cancer of the prostate.
PSA concentrations in serum is an important component of the complex research aimed at identifying prostate cancer. Initial PSA levels below 4 ng / ml in patients receiving dutasteride, does not exclude the diagnosis of prostate cancer.
Dutasteride is absorbed through the skin, therefore, women and children should avoid contact with the active substance. In the case of such a contact should be immediately rinsed corresponding portion of the skin with soap and water. Hypersensitivity to dutasteride and other 5α-reductase inhibitors; contraindicated for use in women and children.
